Baseline Characteristics of Participants in the ASPREE (ASPirin in Reducing Events in the Elderly) Study

There are no primary prevention trials of aspirin with relevant geriatric outcomes in elderly people. ASPirin in Reducing Events in the Elderly (ASPREE) is a placebo-controlled trial of low-dose aspirin that will determine whether 5 years of daily 100-mg enteric-coated aspirin extends disability-fre...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	The journals of gerontology. Series A, Biological sciences and medical sciences Ročník 72; číslo 11; s. 1586
Hlavní autori:	McNeil, John J, Woods, Robyn L, Nelson, Mark R, Murray, Anne M, Reid, Christopher M, Kirpach, Brenda, Storey, Elsdon, Shah, Raj C, Wolfe, Rory S, Tonkin, Andrew M, Newman, Anne B, Williamson, Jeff D, Lockery, Jessica E, Margolis, Karen L, Ernst, Michael E, Abhayaratna, Walter P, Stocks, Nigel, Fitzgerald, Sharyn M, Trevaks, Ruth E, Orchard, Suzanne G, Beilin, Lawrence J, Donnan, Geoffrey A, Gibbs, Peter, Johnston, Colin I, Grimm, Richard H
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	United States 01.11.2017
Predmet:	Activities of Daily Living Administration, Oral Aged Aged, 80 and over Aging - drug effects Aspirin - administration & dosage Australia - epidemiology Cardiovascular Diseases - epidemiology Cardiovascular Diseases - prevention & control Cyclooxygenase Inhibitors - administration & dosage Dementia - epidemiology Dementia - prevention & control Disability Evaluation Disabled Persons - rehabilitation Disabled Persons - statistics & numerical data Dose-Response Relationship, Drug Double-Blind Method Female Humans Incidence Male Prognosis Quality of Life United States - epidemiology Disability Clinical trial Primary prevention Dementia
ISSN:	1758-535X, 1758-535X
On-line prístup:	Zistit podrobnosti o prístupe
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Abstract	There are no primary prevention trials of aspirin with relevant geriatric outcomes in elderly people. ASPirin in Reducing Events in the Elderly (ASPREE) is a placebo-controlled trial of low-dose aspirin that will determine whether 5 years of daily 100-mg enteric-coated aspirin extends disability-free and dementia-free life in a healthy elderly population and whether these benefits outweigh the risks. Set in primary care, this randomized double-blind placebo-controlled trial has a composite primary endpoint of death, incident dementia or persistent physical disability. Participants aged 70+ years (non-minorities) or 65+ years (U.S. minorities) were free of cardiovascular disease, dementia, or physical disability and without a contraindication to, or indication for, aspirin. Baseline data include physical and lifestyle, personal and family medical history, hemoglobin, fasting glucose, creatinine, lipid panel, urinary albumin:creatinine ratio, cognition (3MS, HVLT-R, COWAT, SDMT), mood (CES-D-10), physical function (gait speed, grip strength), Katz activities of daily living and quality of life (SF-12). Recruitment ended in December 2014 with 16,703 Australian and 2,411 U.S. participants, a median age of 74 (range 65-98) years and 56% women. Approximately 55% of the U.S. cohort were from minority groups; 9% of the total cohort. Proportions with hypertension, overweight, and chronic kidney disease were similar to age-matched populations from both countries although lower percentages had diabetes, dyslipidemia, and osteoarthritis. Findings from ASPREE will be generalizable to a healthier older population in both countries and will assess whether the broad benefits of daily low-dose aspirin in prolonging independent life outweigh the risks.
AbstractList	There are no primary prevention trials of aspirin with relevant geriatric outcomes in elderly people. ASPirin in Reducing Events in the Elderly (ASPREE) is a placebo-controlled trial of low-dose aspirin that will determine whether 5 years of daily 100-mg enteric-coated aspirin extends disability-free and dementia-free life in a healthy elderly population and whether these benefits outweigh the risks. Set in primary care, this randomized double-blind placebo-controlled trial has a composite primary endpoint of death, incident dementia or persistent physical disability. Participants aged 70+ years (non-minorities) or 65+ years (U.S. minorities) were free of cardiovascular disease, dementia, or physical disability and without a contraindication to, or indication for, aspirin. Baseline data include physical and lifestyle, personal and family medical history, hemoglobin, fasting glucose, creatinine, lipid panel, urinary albumin:creatinine ratio, cognition (3MS, HVLT-R, COWAT, SDMT), mood (CES-D-10), physical function (gait speed, grip strength), Katz activities of daily living and quality of life (SF-12). Recruitment ended in December 2014 with 16,703 Australian and 2,411 U.S. participants, a median age of 74 (range 65-98) years and 56% women. Approximately 55% of the U.S. cohort were from minority groups; 9% of the total cohort. Proportions with hypertension, overweight, and chronic kidney disease were similar to age-matched populations from both countries although lower percentages had diabetes, dyslipidemia, and osteoarthritis. Findings from ASPREE will be generalizable to a healthier older population in both countries and will assess whether the broad benefits of daily low-dose aspirin in prolonging independent life outweigh the risks. There are no primary prevention trials of aspirin with relevant geriatric outcomes in elderly people. ASPirin in Reducing Events in the Elderly (ASPREE) is a placebo-controlled trial of low-dose aspirin that will determine whether 5 years of daily 100-mg enteric-coated aspirin extends disability-free and dementia-free life in a healthy elderly population and whether these benefits outweigh the risks.BACKGROUNDThere are no primary prevention trials of aspirin with relevant geriatric outcomes in elderly people. ASPirin in Reducing Events in the Elderly (ASPREE) is a placebo-controlled trial of low-dose aspirin that will determine whether 5 years of daily 100-mg enteric-coated aspirin extends disability-free and dementia-free life in a healthy elderly population and whether these benefits outweigh the risks.Set in primary care, this randomized double-blind placebo-controlled trial has a composite primary endpoint of death, incident dementia or persistent physical disability. Participants aged 70+ years (non-minorities) or 65+ years (U.S. minorities) were free of cardiovascular disease, dementia, or physical disability and without a contraindication to, or indication for, aspirin. Baseline data include physical and lifestyle, personal and family medical history, hemoglobin, fasting glucose, creatinine, lipid panel, urinary albumin:creatinine ratio, cognition (3MS, HVLT-R, COWAT, SDMT), mood (CES-D-10), physical function (gait speed, grip strength), Katz activities of daily living and quality of life (SF-12).METHODSSet in primary care, this randomized double-blind placebo-controlled trial has a composite primary endpoint of death, incident dementia or persistent physical disability. Participants aged 70+ years (non-minorities) or 65+ years (U.S. minorities) were free of cardiovascular disease, dementia, or physical disability and without a contraindication to, or indication for, aspirin. Baseline data include physical and lifestyle, personal and family medical history, hemoglobin, fasting glucose, creatinine, lipid panel, urinary albumin:creatinine ratio, cognition (3MS, HVLT-R, COWAT, SDMT), mood (CES-D-10), physical function (gait speed, grip strength), Katz activities of daily living and quality of life (SF-12).Recruitment ended in December 2014 with 16,703 Australian and 2,411 U.S. participants, a median age of 74 (range 65-98) years and 56% women. Approximately 55% of the U.S. cohort were from minority groups; 9% of the total cohort. Proportions with hypertension, overweight, and chronic kidney disease were similar to age-matched populations from both countries although lower percentages had diabetes, dyslipidemia, and osteoarthritis.RESULTSRecruitment ended in December 2014 with 16,703 Australian and 2,411 U.S. participants, a median age of 74 (range 65-98) years and 56% women. Approximately 55% of the U.S. cohort were from minority groups; 9% of the total cohort. Proportions with hypertension, overweight, and chronic kidney disease were similar to age-matched populations from both countries although lower percentages had diabetes, dyslipidemia, and osteoarthritis.Findings from ASPREE will be generalizable to a healthier older population in both countries and will assess whether the broad benefits of daily low-dose aspirin in prolonging independent life outweigh the risks.DISCUSSIONFindings from ASPREE will be generalizable to a healthier older population in both countries and will assess whether the broad benefits of daily low-dose aspirin in prolonging independent life outweigh the risks.
Author	Shah, Raj C Nelson, Mark R Donnan, Geoffrey A Woods, Robyn L Williamson, Jeff D Fitzgerald, Sharyn M Orchard, Suzanne G Storey, Elsdon Lockery, Jessica E Margolis, Karen L Reid, Christopher M Abhayaratna, Walter P Newman, Anne B Beilin, Lawrence J Kirpach, Brenda Gibbs, Peter McNeil, John J Grimm, Richard H Ernst, Michael E Stocks, Nigel Trevaks, Ruth E Wolfe, Rory S Tonkin, Andrew M Murray, Anne M Johnston, Colin I
Author_xml	– sequence: 1 givenname: John J surname: McNeil fullname: McNeil, John J organization: Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Victoria, Australia – sequence: 2 givenname: Robyn L surname: Woods fullname: Woods, Robyn L organization: Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Victoria, Australia – sequence: 3 givenname: Mark R surname: Nelson fullname: Nelson, Mark R organization: Menzies Institute for Medical Research, University of Tasmania, Hobart, Australia – sequence: 4 givenname: Anne M surname: Murray fullname: Murray, Anne M organization: Division of Geriatrics, Department of Medicine, Hennepin County Medical Center and University of Minnesota, Minneapolis – sequence: 5 givenname: Christopher M surname: Reid fullname: Reid, Christopher M organization: School of Public Health, Curtin University, Perth, Western Australia, Australia – sequence: 6 givenname: Brenda surname: Kirpach fullname: Kirpach, Brenda organization: Berman Center for Outcomes and Clinical Research, Minneapolis Medical Research Foundation, Hennepin County Medical Center, Minnesota – sequence: 7 givenname: Elsdon surname: Storey fullname: Storey, Elsdon organization: Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Victoria, Australia – sequence: 8 givenname: Raj C surname: Shah fullname: Shah, Raj C organization: Department of Family Medicine and Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, Illinois – sequence: 9 givenname: Rory S surname: Wolfe fullname: Wolfe, Rory S organization: Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Victoria, Australia – sequence: 10 givenname: Andrew M surname: Tonkin fullname: Tonkin, Andrew M organization: Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Victoria, Australia – sequence: 11 givenname: Anne B surname: Newman fullname: Newman, Anne B organization: Center for Aging and Population Health, University of Pittsburgh, Pennsylvania – sequence: 12 givenname: Jeff D surname: Williamson fullname: Williamson, Jeff D organization: Gerontology and Geriatric Medicine, Wake Forest School of Medicine, Department of Internal Medicine, Winston-Salem, North Carolina – sequence: 13 givenname: Jessica E surname: Lockery fullname: Lockery, Jessica E organization: Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Victoria, Australia – sequence: 14 givenname: Karen L surname: Margolis fullname: Margolis, Karen L organization: HealthPartners Institute, Minneapolis, Minnesota – sequence: 15 givenname: Michael E surname: Ernst fullname: Ernst, Michael E organization: Department of Pharmacy Practice and Science, College of Pharmacy and Department of Family Medicine, Carver College of Medicine, University of Iowa – sequence: 16 givenname: Walter P surname: Abhayaratna fullname: Abhayaratna, Walter P organization: Cardiovascular Medicine, College of Medicine, Biology and Environment, Australian National University, Canberra, Australian Capital Territory, Australia – sequence: 17 givenname: Nigel surname: Stocks fullname: Stocks, Nigel organization: Discipline of General Practice, University of Adelaide, South Australia, Australia – sequence: 18 givenname: Sharyn M surname: Fitzgerald fullname: Fitzgerald, Sharyn M organization: Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Victoria, Australia – sequence: 19 givenname: Ruth E surname: Trevaks fullname: Trevaks, Ruth E organization: Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Victoria, Australia – sequence: 20 givenname: Suzanne G surname: Orchard fullname: Orchard, Suzanne G organization: Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Victoria, Australia – sequence: 21 givenname: Lawrence J surname: Beilin fullname: Beilin, Lawrence J organization: School of Medicine and Pharmacology, Royal Perth Hospital Unit, University of Western Australia, Perth, Australia – sequence: 22 givenname: Geoffrey A surname: Donnan fullname: Donnan, Geoffrey A organization: Florey Institute of Neuroscience and Mental Health, University of Melbourne, Parkville, Victoria, Australia – sequence: 23 givenname: Peter surname: Gibbs fullname: Gibbs, Peter organization: The Walter and Eliza Hall Institute of Medical Research, Melbourne, Victoria, Australia – sequence: 24 givenname: Colin I surname: Johnston fullname: Johnston, Colin I organization: Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Victoria, Australia – sequence: 25 givenname: Richard H surname: Grimm fullname: Grimm, Richard H organization: Berman Center for Outcomes and Clinical Research, Minneapolis Medical Research Foundation, Hennepin County Medical Center, Minnesota
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/28329340$$D View this record in MEDLINE/PubMed
BookMark	eNpNkEtLw0AUhQep2Icu3cos6yJ2nk2yrCU-oGBpFdyFmcxNO5JO6kyi9N8bsUIvl3sOh4-zuEPUc7UDhK4puaMk5ZMN-Nqpyab65oKdoQGNZRJJLt97J76PhiF8kN-R7AL1WcJZygUZoO29ClBZB3i-VV4VDXgbGlsEXJd4qXxn7V65JmDrcLMFPFsvV1mGx51a32XdrsC0hXUbnH3BCZlVBnx1uMXrpjWHS3ReqirA1VFH6O0he50_RYuXx-f5bBEVIqFNBEIbWhYyZSpOtIwlLZnQmsdghGaaaCBxwoyk0pR6mkI65VMDEmTaHZVSNkLjv969rz9bCE2-s6GAqlIO6jbkNEmIiBmjvENvjmird2Dyvbc75Q_5_3fYD-icaaM
CitedBy_id	crossref_primary_10_1016_j_jagp_2025_02_012 crossref_primary_10_1080_14656566_2020_1817389 crossref_primary_10_3389_fneur_2022_950644 crossref_primary_10_1177_104012371903100215 crossref_primary_10_1016_j_ebiom_2025_105826 crossref_primary_10_1080_13854046_2018_1488996 crossref_primary_10_1002_art_42156 crossref_primary_10_1038_s41467_019_14079_0 crossref_primary_10_1093_geronb_gby004 crossref_primary_10_1016_j_cct_2023_107231 crossref_primary_10_1002_gps_70065 crossref_primary_10_1016_j_neurobiolaging_2023_05_011 crossref_primary_10_3389_fnagi_2022_1063721 crossref_primary_10_1016_j_conctc_2018_05_015 crossref_primary_10_1111_dom_16579 crossref_primary_10_1080_13854046_2020_1730444 crossref_primary_10_1007_s11357_023_00941_z crossref_primary_10_1371_journal_pone_0226868 crossref_primary_10_3390_biomedicines13081977 crossref_primary_10_1002_alz_70065 crossref_primary_10_1097_HJH_0000000000003599 crossref_primary_10_1055_a_1711_1395 crossref_primary_10_1002_cpt_1959 crossref_primary_10_1016_j_cct_2020_106095 crossref_primary_10_1038_s41380_025_03145_3 crossref_primary_10_1007_s11883_020_00851_x crossref_primary_10_5694_mja2_12060 crossref_primary_10_1002_phar_2652 crossref_primary_10_1007_s11136_021_03021_x crossref_primary_10_1210_clinem_dgae099 crossref_primary_10_1038_s43587_022_00203_1 crossref_primary_10_1002_ehf2_14101 crossref_primary_10_1097_HC9_0000000000000756 crossref_primary_10_1093_cercor_bhaa293 crossref_primary_10_1097_PSY_0000000000000989 crossref_primary_10_1038_s41525_021_00211_x crossref_primary_10_1007_s11357_024_01438_z crossref_primary_10_1093_aje_kwad168 crossref_primary_10_1093_eurheartj_ehaf514 crossref_primary_10_1111_acel_13384 crossref_primary_10_1111_resp_14279 crossref_primary_10_1016_j_ebiom_2024_104997 crossref_primary_10_1111_cen_14401 crossref_primary_10_1136_openhrt_2021_001710 crossref_primary_10_1002_gps_5644 crossref_primary_10_1016_j_archger_2022_104694 crossref_primary_10_1111_jgs_16468 crossref_primary_10_1186_s13063_022_06132_z crossref_primary_10_1016_j_conctc_2020_100667 crossref_primary_10_1002_alz_13006 crossref_primary_10_1002_cncr_35503 crossref_primary_10_1001_jamanetworkopen_2024_58591 crossref_primary_10_1001_jamaophthalmol_2024_1584 crossref_primary_10_1093_ajh_hpz192 crossref_primary_10_1515_cclm_2024_0848 crossref_primary_10_1002_alz_14055 crossref_primary_10_1016_j_osep_2024_09_002 crossref_primary_10_1182_blood_2019003487 crossref_primary_10_1186_s12877_023_04247_9 crossref_primary_10_1136_jech_2023_221860 crossref_primary_10_1038_s41433_023_02754_y crossref_primary_10_3389_fmed_2022_917254 crossref_primary_10_1161_HYPERTENSIONAHA_120_16209 crossref_primary_10_1016_j_xkme_2022_100583 crossref_primary_10_1093_ije_dyy279 crossref_primary_10_3233_JAD_201349 crossref_primary_10_1016_j_ophtha_2024_01_033 crossref_primary_10_1371_journal_pone_0294743 crossref_primary_10_1111_ceo_14233 crossref_primary_10_1177_1747493017741383 crossref_primary_10_1080_13697137_2025_2539854 crossref_primary_10_1111_jgs_19440 crossref_primary_10_1038_s41523_021_00360_3 crossref_primary_10_1111_jgs_18353 crossref_primary_10_7326_M23_0675 crossref_primary_10_1136_bmjph_2023_000709 crossref_primary_10_1210_clinem_dgaa429 crossref_primary_10_1002_dad2_12353 crossref_primary_10_1001_jamanetworkopen_2023_25803 crossref_primary_10_1002_phar_2461 crossref_primary_10_1007_s11136_018_2040_z crossref_primary_10_3390_cancers13225815 crossref_primary_10_1038_s41598_023_29586_w crossref_primary_10_1007_s11357_025_01598_6 crossref_primary_10_1093_jnci_djaa114 crossref_primary_10_1007_s12603_022_1860_2 crossref_primary_10_1016_j_ijcard_2021_07_004 crossref_primary_10_1001_jamanetworkopen_2022_14647 crossref_primary_10_1016_j_ijcard_2019_11_152 crossref_primary_10_1093_ckj_sfaf119 crossref_primary_10_1007_s12603_023_1884_2 crossref_primary_10_1111_liv_15725 crossref_primary_10_2217_epi_2020_0236 crossref_primary_10_1111_cen_14898 crossref_primary_10_1007_s40266_025_01199_0 crossref_primary_10_1111_jgs_17435 crossref_primary_10_3233_ADR_200194 crossref_primary_10_3390_cancers13143533 crossref_primary_10_1002_dad2_70010 crossref_primary_10_1093_ehjcvp_pvae085 crossref_primary_10_1212_WNL_0000000000213743 crossref_primary_10_3390_cancers13071495 crossref_primary_10_1002_alz_13113 crossref_primary_10_1111_jgs_18757 crossref_primary_10_3390_jcm11175117 crossref_primary_10_1177_17151635211018725 crossref_primary_10_1186_s12889_024_17794_6 crossref_primary_10_1002_dad2_12226 crossref_primary_10_1016_j_kint_2020_08_011 crossref_primary_10_1016_j_neurobiolaging_2021_10_007 crossref_primary_10_1001_jama_2022_3337 crossref_primary_10_1111_jep_13107 crossref_primary_10_1038_s44355_025_00021_3 crossref_primary_10_1186_s13578_021_00716_z crossref_primary_10_1007_s11357_024_01435_2 crossref_primary_10_1080_13697137_2023_2166824 crossref_primary_10_1177_13872877251362202 crossref_primary_10_1016_j_cjca_2025_06_003 crossref_primary_10_1002_gps_5601 crossref_primary_10_1186_s13063_019_3789_2 crossref_primary_10_1016_j_ahjo_2022_100117 crossref_primary_10_1002_dad2_12056 crossref_primary_10_1056_NEJMoa1800722 crossref_primary_10_1007_s11357_017_0003_x crossref_primary_10_1056_NEJMoa1803955 crossref_primary_10_1210_jc_2019_00743 crossref_primary_10_3390_cancers15041017 crossref_primary_10_1177_08982643221083118 crossref_primary_10_1159_000541895 crossref_primary_10_1016_j_jad_2025_05_014 crossref_primary_10_1007_s11136_020_02723_y crossref_primary_10_1111_jjns_70005 crossref_primary_10_1371_journal_pone_0236031 crossref_primary_10_1038_s41431_018_0279_z crossref_primary_10_1111_jch_13934 crossref_primary_10_1136_bmjopen_2020_042261 crossref_primary_10_3390_nu16172978 crossref_primary_10_1161_JAHA_120_019613 crossref_primary_10_5694_mja2_50842 crossref_primary_10_1111_ajag_70036 crossref_primary_10_1080_13697137_2025_2470458 crossref_primary_10_1016_j_lanwpc_2023_100963 crossref_primary_10_1016_j_neuroimage_2020_117196 crossref_primary_10_1007_s11606_020_06550_2 crossref_primary_10_1161_CIRCGEN_120_002938 crossref_primary_10_3390_nu17091415
ContentType	Journal Article
Copyright	The Author 2017. Published by Oxford University Press on behalf of The Gerontological Society of America. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Copyright_xml	– notice: The Author 2017. Published by Oxford University Press on behalf of The Gerontological Society of America. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
CorporateAuthor	ASPREE Investigator Group
CorporateAuthor_xml	– name: ASPREE Investigator Group
DBID	CGR CUY CVF ECM EIF NPM 7X8
DOI	10.1093/gerona/glw342
DatabaseName	Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic
DatabaseTitle	MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic
DatabaseTitleList	MEDLINE MEDLINE - Academic
Database_xml	– sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database
DeliveryMethod	no_fulltext_linktorsrc
Discipline	Medicine Social Welfare & Social Work
EISSN	1758-535X
ExternalDocumentID	28329340
Genre	Randomized Controlled Trial Multicenter Study Journal Article
GrantInformation_xml	– fundername: NIA NIH HHS grantid: P30 AG024827 – fundername: NIA NIH HHS grantid: U01 AG029824
GroupedDBID	--- -ET .2P .I3 .ZR 0R~ 18M 1TH 29L 2FS 4.4 48X 5GY 5RE 5VS 5WD 6PF 70D 85S AABZA AACZT AAIMJ AAJKP AAJQQ AAMVS AAOGV AAPNW AAPQZ AAPXW AAQQT AARHZ AAUAY AAUQX AAVAP AAVLN AAWTL ABDFA ABEJV ABEUO ABGNP ABIXL ABKDP ABMNT ABNHQ ABNKS ABPBX ABPPZ ABPQP ABPTD ABQLI ABVGC ABWJO ABWST ABXVV ABXZS ABZBJ ACGOD ACKOT ACNCT ACPRK ACUFI ACUTJ ACUTO ADBBV ADEYI ADGKP ADGZP ADHKW ADHZD ADIPN ADMHG ADNBA ADOCK ADQBN ADRTK ADVEK ADYKR ADYVW AEGPL AEJOX AEKSI AELWJ AEMDU AEMQT AENZO AEPUE AETBJ AEWNT AFFZL AFGWE AFIYH AFOFC AFXAL AGINJ AGKEF AGQXC AGSYK AGUTN AHMBA AHMMS AHXPO AIJHB AJBYB AJEEA ALMA_UNASSIGNED_HOLDINGS ALUQC ALXQX APIBT APWMN ARIXL ATGXG BAYMD BCRHZ BEYMZ BKOMP BQDIO BSWAC BTRTY BVRKM BZKTN C45 CDBKE CGR CQJDY CUY CVF CWPEY CZ4 DAKXR DILTD D~K EBS ECM EE~ EIF EJD EMOBN ENERS F5P F9B FECEO FHSFR FLUFQ FOEOM FOTVD FQBLK GAUVT GJXCC H13 H5~ HAR HF~ HW0 HZ~ IOX J21 KAQDR KOO KOP KSI KSN L7B M-Z MHKGH ML0 N9A NGC NLBLG NOMLY NOYVH NPM NU- NVLIB O9- OAUYM OAWHX OBOKY OCZFY ODMLO OJQWA OJZSN OPAEJ OVD OWPYF PAFKI PEELM PQQKQ Q1. Q5Y RD5 RGE ROX ROZ RUSNO RW1 RXO RXW SJN TAE TEORI TJX TLC UPT WH7 X7H XZL YAYTL YKOAZ YKV YQT YXANX YZZ ~91 7X8
ID	FETCH-LOGICAL-c481t-e4bd1fc592a78b5751f24bb37ed4b2b0be0782d515dfb69e9636de5e59e5ea912
IEDL.DBID	7X8
ISICitedReferencesCount	182
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000412856300018&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	1758-535X
IngestDate	Thu Oct 02 07:42:09 EDT 2025 Mon Jul 21 05:46:34 EDT 2025
IsDoiOpenAccess	false
IsOpenAccess	true
IsPeerReviewed	true
IsScholarly	true
Issue	11
Keywords	Disability Clinical trial Primary prevention Dementia
Language	English
License	The Author 2017. Published by Oxford University Press on behalf of The Gerontological Society of America. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c481t-e4bd1fc592a78b5751f24bb37ed4b2b0be0782d515dfb69e9636de5e59e5ea912
Notes	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Undefined-3
OpenAccessLink	https://academic.oup.com/biomedgerontology/article-pdf/72/11/1586/27155304/glw342.pdf
PMID	28329340
PQID	1880472213
PQPubID	23479
ParticipantIDs	proquest_miscellaneous_1880472213 pubmed_primary_28329340
PublicationCentury	2000
PublicationDate	2017-11-01
PublicationDateYYYYMMDD	2017-11-01
PublicationDate_xml	– month: 11 year: 2017 text: 2017-11-01 day: 01
PublicationDecade	2010
PublicationPlace	United States
PublicationPlace_xml	– name: United States
PublicationTitle	The journals of gerontology. Series A, Biological sciences and medical sciences
PublicationTitleAlternate	J Gerontol A Biol Sci Med Sci
PublicationYear	2017
References	30668672 - J Gerontol A Biol Sci Med Sci. 2019 Apr 23;74(5):748
References_xml	– reference: 30668672 - J Gerontol A Biol Sci Med Sci. 2019 Apr 23;74(5):748
SSID	ssj0000052
Score	2.6057985
Snippet	There are no primary prevention trials of aspirin with relevant geriatric outcomes in elderly people. ASPirin in Reducing Events in the Elderly (ASPREE) is a...
SourceID	proquest pubmed
SourceType	Aggregation Database Index Database
StartPage	1586
SubjectTerms	Activities of Daily Living Administration, Oral Aged Aged, 80 and over Aging - drug effects Aspirin - administration & dosage Australia - epidemiology Cardiovascular Diseases - epidemiology Cardiovascular Diseases - prevention & control Cyclooxygenase Inhibitors - administration & dosage Dementia - epidemiology Dementia - prevention & control Disability Evaluation Disabled Persons - rehabilitation Disabled Persons - statistics & numerical data Dose-Response Relationship, Drug Double-Blind Method Female Humans Incidence Male Prognosis Quality of Life United States - epidemiology
Title	Baseline Characteristics of Participants in the ASPREE (ASPirin in Reducing Events in the Elderly) Study
URI	https://www.ncbi.nlm.nih.gov/pubmed/28329340 https://www.proquest.com/docview/1880472213
Volume	72
WOSCitedRecordID	wos000412856300018&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText
inHoldings	1
isFullTextHit
isPrint
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1bS8MwFA7qRHzxMm_TKRFE9CFsTdPbk8wx8cGN4QX3NpL2ZA5HO9up7N970nVeHgRBKCmEFkrOl5yvOSfnI-QE0Om6SMSZzQPNBDJcFvgQMgSPrmsuXB3llr7xOh2_1wu6xYZbVqRVztfEfKGOktDskddM3TBT2NCyL8YvzKhGmehqIaGxSEo2UhmDaq_nf6O_ueIOekifObbTK2ps4k98bQApMt3aYPRuG5X239hl7mWu1v_7fRtkreCXtDEDxCZZgLhMVtpFBL1MqrPzuPQRRlqmQE_pvCNJn7fI06XMT6gDbf6s5EwTTbuyyMGOJxkdxhS5I23coQ1b9AzvwxT78Lo11WDRI9KWyaX8fLJl9MBH03NqUhen2-ThqnXfvGaFGAMLhW9NGAgVWTp0Ai49X5loDVpSKduDSCiu6goM2YiQHkVauQHgxHYjcMAJsJGBxXfIUpzEsEeoE3LP0sINpVDC5Za0tbC4RLIkI0DIVMjxfIj7CHYTwZAxJK9Z_2uQK2R3Zqf-eFaVo280lwJb1Pf_8PYBWeXGPednCqukpHGqwyFZDt8mwyw9ylGEbafb_gCU49HE
linkProvider	ProQuest
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Baseline+Characteristics+of+Participants+in+the+ASPREE+%28ASPirin+in+Reducing+Events+in+the+Elderly%29+Study&rft.jtitle=The+journals+of+gerontology.+Series+A%2C+Biological+sciences+and+medical+sciences&rft.au=McNeil%2C+John+J&rft.au=Woods%2C+Robyn+L&rft.au=Nelson%2C+Mark+R&rft.au=Murray%2C+Anne+M&rft.date=2017-11-01&rft.issn=1758-535X&rft.eissn=1758-535X&rft.volume=72&rft.issue=11&rft.spage=1586&rft_id=info:doi/10.1093%2Fgerona%2Fglw342&rft.externalDBID=NO_FULL_TEXT
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1758-535X&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1758-535X&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1758-535X&client=summon